Ross Camidge, MD, PhD of the University of Colorado Cancer Center explains the Phase 3 ALTA 1L trial, which led to the approval of brigatinib as a first-line therapy to treat anaplastic lymphoma kinase-positive (ALK+) metastatic nnon-small cell lung cancer (NSCLC).
Approximately 3-5% of metastatic NSCLC cases have alterations in the ALK gene and as a result, it is considered a rare cancer.
In the 3 ALTA 1L trial, the group of patients given brigatinib showed a progressive-free survival (PFS) of 24 months compared to the significantly lower PFS of 11 months in the group receiving crizotinib. The brigantinib group also had superior overall response rates (74% vs 62%) and superior intracranial overall response rates (78% vs 26%) compared to the crizotinib-treated group.
To learn more about this and other rare cancers, visit checkrare.com/diseases/cancers/
